{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T03:50:42Z","timestamp":1788666642056,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmoop.2025.104291","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T21:07:56Z","timestamp":1739826476000},"page":"104291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":false,"given":"A.","family":"Naing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0944-7418","authenticated-orcid":false,"given":"M.","family":"McKean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2503-6133","authenticated-orcid":false,"given":"L.S.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Sommerhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2862-7089","authenticated-orcid":false,"given":"N.M.","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-0394","authenticated-orcid":false,"given":"I.-M.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Le Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.H.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.104291_bib2","author":"AstraZeneca Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104291_bib6","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/S0021-9258(18)49895-X","article-title":"The interleukin-2 receptor","volume":"266","author":"Waldmann","year":"1991","journal-title":"J\u00a0Biol Chem"},{"issue":"21","key":"10.1016\/j.esmoop.2025.104291_bib7","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.200363097","article-title":"IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104291_bib9","first-page":"105","article-title":"Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy","volume":"14","author":"Waldmann","year":"2001","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.esmoop.2025.104291_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104291_bib11","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1158\/2326-6066.CIR-17-0279","article-title":"IL15 infusion of cancer patients expands the subpopulation of cytotoxic CD56bright NK cells and increases NK-cell cytokine release capabilities","volume":"5","author":"Dubois","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.104291_bib14","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A\u00a0first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.esmoop.2025.104291_bib15","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1172\/JCI42002","article-title":"Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma","volume":"120","author":"Eyles","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.esmoop.2025.104291_bib16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fonc.2013.00090","article-title":"The tumor microenvironment: a pitch for multiple players","volume":"3","author":"Schiavoni","year":"2013","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104291_bib17","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.1500300","article-title":"IL-15 superagonist-mediated immunotoxicity: role of NK cells and IFN-gamma","volume":"195","author":"Guo","year":"2015","journal-title":"J\u00a0Immunol"},{"issue":"suppl 5","key":"10.1016\/j.esmoop.2025.104291_bib18","article-title":"THOR-707, a novel not-alpha IL-2, promotes all key immune system anti-tumoral actions of IL-2 without eliciting vascular leak syndrome (VLS)","volume":"30","author":"Milla","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib19","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.esmoop.2025.104291_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.104291_bib21","article-title":"Safety, PK\/PD, and anti-tumor activity of RO6874281, an engineered variant of interleukin-2 (IL-2v) targeted to tumor-associated fibroblasts via binding to fibroblast activation protein (FAP)","volume":"36","author":"Soerensen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2025.104291_bib22","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1538-7445.AM2019-1552","article-title":"Abstract 1552: A novel PD1-IL2v immunocytokine for preferential cis-activation of IL-2R signaling on PD-1 expressing T cell subsets strongly potentiates anti-tumor T cell activity of PD-1 checkpoint inhibition and IL-2R-beta-gamma agonism","volume":"79","author":"Klein","year":"2019","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104291_bib23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104291_bib24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/2326-6066.CIR-21-0058","article-title":"An engineered IL15 cytokine mutein fused to an anti-PD1 improves intratumoral T-cell function and antitumor immunity","volume":"9","author":"Xu","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.esmoop.2025.104291_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0298240","article-title":"Pharmacokinetics, pharmacodynamics, and toxicity of a PD-1-targeted IL-15 in cynomolgus monkeys","volume":"19","author":"Ji","year":"2024","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.esmoop.2025.104291_bib26","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1200\/JCO.2007.12.1012","article-title":"Translation of innovative designs into phase I trials","volume":"25","author":"Rogatko","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib27","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1021\/acs.jproteome.0c00641","article-title":"Multiplatform approach for plasma proteomics: complementarity of olink proximity extension assay technology to mass spectrometry-based protein profiling","volume":"20","author":"Petrera","year":"2021","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.esmoop.2025.104291_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184703","article-title":"Research progress of interleukin-15 in cancer immunotherapy","volume":"14","author":"Cai","year":"2023","journal-title":"Front Pharmacol"},{"issue":"13","key":"10.1016\/j.esmoop.2025.104291_bib29","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.3390\/ijms23137311","article-title":"Interleukin 15 in cell-based cancer immunotherapy","volume":"23","author":"Zhou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104291_bib30","article-title":"All eyes are on IL-15 in early phase studies","volume":"25","author":"Megan","year":"2024","journal-title":"Oncol Live\u00ae"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.104291_bib31","article-title":"1183 ASKG915 \u2013 an anti-PD-1 antibody-IL-15 prodrug fusion molecule with enhanced therapeutic potentials","volume":"10","author":"Shanebeck","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.esmoop.2025.104291_bib32","article-title":"A\u00a0phase 1\/2, open label, first-in-human, dose escalation and expansion study of SAR445877 administered as monotherapy in adults with advanced solid tumors","volume":"11","author":"Gutierrez","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.104291_bib33","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R\u03b1, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104291_bib34","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1200\/JCO.2022.40.16_suppl.2502","article-title":"Interim safety and efficacy results from AURELIO-03: a phase 1 dose escalation study of the IL-2\/IL-15 receptor \u03b2\u03b3 superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors","volume":"40","author":"Garralda","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.104291_bib35","article-title":"AURELIO-04: a phase 2, open-label, single-arm, multicenter study to determine the efficacy and safety of SOT101 in combination with pembrolizumab in patients with selected advanced solid tumors","volume":"10","author":"Champiat","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2025.104291_bib37","first-page":"A1007","article-title":"NKTR-255+cetuximab in patients with solid tumors: interim safety and efficacy results from the phase 1b dose-escalation study","volume":"9","author":"Altan","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.104291_bib38","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2022.40.16_suppl.4508","article-title":"Final clinical results of pivotal trial of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC)","volume":"40","author":"Chamie","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4062\/biomolther.2023.196","article-title":"Current development status of cytokines for cancer immunotherapy","volume":"32","author":"Song","year":"2024","journal-title":"Biomol Ther (Seoul)"},{"issue":"1","key":"10.1016\/j.esmoop.2025.104291_bib41","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymthe.2022.08.016","article-title":"A\u00a0novel anti-PD-L1\/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity","volume":"31","author":"Shi","year":"2023","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2025.104291_bib42","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925001590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T23:48:08Z","timestamp":1749599288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925001590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2059702925001590"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104291","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-in-human phase I study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of PF-07209960 in patients with advanced or metastatic solid tumors","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.104291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"104291"}}